Plasma Metabolomics Reveals Diagnostic Biomarkers and Risk Factors for Esophageal Squamous Cell Carcinoma.

Yu, Mengjie; Wen, Wei; Yi, Xin; Zhu, Wei; Aa, Jiye; Wang, Guangji

Yu, Mengjie; Wen, Wei; Yi, Xin; Zhu, Wei; Aa, Jiye; Wang, Guangji.

Afiliação

Yu M; Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Wen W; Department of Thoracic Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi X; Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Zhu W; Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Aa J; Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Wang G; Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.

Front Oncol ; 12: 829350, 2022.

Article em En | MEDLINE | ID: mdl-35198450

Palavras-chave

ESCC (esophageal squamous cell carcinoma); biomarker; esophageal squamous dysplasia; metabolomics; risk factors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google